News

With ArchiMed’s backing, the group is expected to rapidly become a European leader in diagnostics for cutting-edge, precision medical treatments for cancer. January 12, 2021 – Private equity healthcare specialist, ArchiMed, announces its acquisition of the Zyto group of companies, a fully integrated developer, manufacturer and distributor of technologically advanced cancer diagnostics tests and equipment…

The purchase of Syntactx reinforces NAMSA’s position as the world’s leading one-stop shop for complex, outsourced medical device testing. January 5, 2021 – NAMSA, a portfolio company of global private equity healthcare specialist ArchiMed, announces the 100 percent purchase of Syntactx. NAMSA and Syntactx are contract research organizations, offering outsourced services for clinical trials and…

The Eurêka Foundation – the beneficiary – is an integral part of ArchiMed’s mission to sustainably improve lives as an impact investor. November 5, 2020 – Global private equity healthcare specialist ArchiMed announces its latest contribution of several million euros to the Eurêka Foundation, the philanthropy created by its partners when the firm was founded in…

Investment to accelerate NAMSA’s global growth and strategic vision; NAMSA is the third acquisition of MED Platform I, ArchiMed’s recently closed €1 billion mid-cap buy-and-build fund for the healthcare sector.   September 1, 2020 – Private equity healthcare specialist ArchiMed has acquired from the founding Gorski Family a majority stake in NAMSA, the only full…

The oversubscribed fund closed above the global private equity healthcare specialist’s €800 million target, notwithstanding the impact of the Covid-19 pandemic. ArchiMed’s €1 billion ($1.2 billion) mid-market buy-and-build fund, MED Platform I, attracted major commitments from a broad range of institutional investors and family offices in both Europe (70 percent) and North America (30 percent).…

ArchiMed’s purchase will accelerate ActiGraph’s expansion within the complex, highly regulated global drug development industry. Private equity healthcare specialist, ArchiMed has acquired ActiGraph, a pioneering developer of wearable, remote monitoring technology for academic studies and drug trials. ActiGraph’s mobility and sleep tracking hardware, software and analysis solutions are the most widely used research-grade monitoring systems…